Department of Gastroenterology, Western General Hospital, Edinburgh, UK.
Centre for Liver and Digestive Disorders, Royal Infirmary of Edinburgh, Edinburgh, UK.
Aliment Pharmacol Ther. 2018 Aug;48(4):423-430. doi: 10.1111/apt.14897. Epub 2018 Jul 4.
Hyaluronic acid is a recognised noninvasive marker of liver fibrosis. However, its prognostic ability has not been extensively studied.
To investigate the ability of an index serum hyaluronic acid measurement to independently predict transplant-free survival in patients with liver disease of varying aetiology and severity.
This was a retrospective single-centre cohort study. Serum hyaluronic acid was measured at the discretion of the attending clinicians, in patients attending the liver clinic, to assess disease severity. Patients with a hyaluronic acid measurement between 1995 and 2010 were identified. Patient characteristics at the point of hyaluronic acid measurement were recorded from medical records. Follow-up was from date of index hyaluronic acid measurement to date of death, date of transplant or censor date (July 01, 2015). Primary outcomes were all-cause and liver-related mortality. Kaplan-Meier analysis was used to compare survival in 3 patient groups with hyaluronic acid levels of <100 μg/L, 100-300 μg/L and >300 μg/L. Survival models were constructed using Cox proportional hazard and prediction accuracy was assessed by Harrell's C-statistic.
Five hundred and eighty nine patients fulfilled inclusion criteria. Median follow-up was 5.6 years (range 0.1-19.7). Transplant-free survival was significantly different between patients with hyaluronic acid <100 μg/L, 100-300 μg/L and >300 μg/L for liver-related as well as all-cause mortality (P < 0.001). Hyaluronic acid level was an independent predictor of survival (liver-related: HR 1.39, 95% CI 1.20-1.60, P < 0.001; all-cause: HR 1.04, 95% CI 1.02-1.06, P = 0.001). The liver-related prediction accuracy of hyaluronic acid was 0.74 (Standard error 0.03).
Index hyaluronic acid measurement can accurately and independently predict liver-related and all-cause mortality in patients with liver disease.
透明质酸是一种公认的非侵入性肝纤维化标志物。然而,其预后能力尚未得到广泛研究。
研究血清透明质酸指数测量值是否能独立预测不同病因和严重程度肝病患者的无移植存活率。
这是一项回顾性单中心队列研究。根据临床医生的判断,在就诊于肝脏科的患者中测量血清透明质酸,以评估疾病严重程度。确定在 1995 年至 2010 年之间进行了透明质酸测量的患者。从病历中记录了透明质酸测量时患者的特征。随访时间从指数透明质酸测量日期到死亡、移植或截止日期(2015 年 7 月 1 日)。主要结局为全因和肝脏相关死亡率。Kaplan-Meier 分析用于比较透明质酸水平<100μg/L、100-300μg/L 和>300μg/L 的 3 组患者的生存情况。使用 Cox 比例风险构建生存模型,并通过 Harrell 的 C 统计评估预测准确性。
589 名患者符合纳入标准。中位随访时间为 5.6 年(范围 0.1-19.7)。透明质酸<100μg/L、100-300μg/L 和>300μg/L 的患者肝相关和全因死亡率差异有统计学意义(P<0.001)。透明质酸水平是生存的独立预测因素(肝相关:HR 1.39,95%CI 1.20-1.60,P<0.001;全因:HR 1.04,95%CI 1.02-1.06,P=0.001)。透明质酸的肝相关预测准确性为 0.74(标准误差 0.03)。
指数透明质酸测量可准确且独立预测肝病患者的肝相关和全因死亡率。